Avalyn Pharma Inc. Common Stock (NASDAQ:AVLN) — Market Cap & Net Worth
Market Cap & Net Worth: Avalyn Pharma Inc. Common Stock (AVLN)
Avalyn Pharma Inc. Common Stock (NASDAQ:AVLN) has a market capitalization of $1.50 Billion ($1.50 Billion) as of August 24, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7256 globally and #2223 in its home market, demonstrating a 4.89% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Avalyn Pharma Inc. Common Stock's stock price $38.37 by its total outstanding shares 44333095 (44.33 Million). Check latest Avalyn Pharma Inc. Common Stock stock price today for real-time trading data and today's change.
Avalyn Pharma Inc. Common Stock Market Cap History: 2026 to 2026
Avalyn Pharma Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $1.70 Billion to $1.70 Billion (0.00% CAGR).
Avalyn Pharma Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Avalyn Pharma Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check AVLN total equity to evaluate the company's book value and shareholders' equity.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AVLN by Market Capitalization
Companies near Avalyn Pharma Inc. Common Stock in the global market cap rankings as of August 24, 2026. Also see AVLN cash generation efficiency for how efficiently the company converts equity into cash flow.
Key companies related to Avalyn Pharma Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #188 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #323 globally with a market cap of $83.19 Billion USD.
- CSL Ltd (AU:CSL): Ranked #475 globally with a market cap of $57.77 Billion USD ( AU$81.65 Billion AUD).
- Samsung Biologics Co Ltd (KO:207940): Ranked #564 globally with a market cap of $48.66 Billion USD ( ₩71.80 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #188 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $548.05 |
| #323 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $83.19 Billion | $834.04 |
| #475 | CSL Ltd | AU:CSL | $57.77 Billion | AU$168.30 |
| #564 | Samsung Biologics Co Ltd | KO:207940 | $48.66 Billion | ₩1551000.00 |
Avalyn Pharma Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Avalyn Pharma Inc. Common Stock's market cap moved from $1.70 Billion to $ 1.70 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.70 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 24th, 2026 the market cap of Avalyn Pharma Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.50 Billion USD |
| MoneyControl | $1.50 Billion USD |
| MarketWatch | $1.50 Billion USD |
| marketcap.company | $1.50 Billion USD |
| Reuters | $1.50 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled fo… Read more